Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05061550 · ClinicalTrials.gov registry record · Phase 2

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 2
Development phase
630
Enrollment target
20
Study locations

NCT05061550 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 630 participants, roughly in line with the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05061550, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 2
Development phase
630 participants
Enrollment target
20
Study locations

Study Summary

The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • DRUG Durvalumab
  • DRUG Dato-DXd
  • DRUG Monalizumab
  • DRUG Oleclumab
  • DRUG AZD0171

Study Locations (20)

Tennessee

  • Research Site - Chattanooga
  • Research Site - Memphis
  • Research Site - Nashville
  • Research Site - Nashville
  • Research Site - Nashville

California

  • Research Site - Los Angeles
  • Research Site - Oakland

Maryland

  • Research Site - Baltimore
  • Research Site - Baltimore

Arkansas

  • Research Site - Little Rock

Connecticut

  • Research Site - New Haven

Florida

  • Research Site - Stuart

Georgia

  • Research Site - Gainesville

Illinois

  • Research Site - Chicago

Trial Details

FieldValue
Enrollment Target 630 participants
Start Date 2022-04-14
Est. Completion 2030-05-28
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05061550

The ClinicalTrials.gov registry entry for NCT05061550 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 630 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Durvalumab is the first listed.

NCT05061550 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Tennessee, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT05061550 about?

NCT05061550 is a clinical study titled "Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer". The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combinat...

What is the current status of trial NCT05061550?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 630 participants. The study started on 2022-04-14. Estimated completion is 2030-05-28.

What conditions does trial NCT05061550 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT05061550?

The interventions under investigation include: Durvalumab (DRUG), Dato-DXd (DRUG), Monalizumab (DRUG), Oleclumab (DRUG), AZD0171 (DRUG).

Who is sponsoring clinical trial NCT05061550?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05061550 being conducted?

This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.